BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 28, 2026
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Dogs and darlings of Wall Street

The biopharma company gainers and decliners for 2019

Jan. 6, 2020
By Peter Winter
Investors warmed to biopharma company equities, particularly in the final quarter of the year, with the BioWorld Biopharmaceutical Index increasing 23% in value during this period, helping the group climb to a respectable 14% for the year after being underwater from April through to September.
Read More

Biggest gainers and losers for the week of Dec. 30, 2019-Jan. 3, 2020

Jan. 3, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-Dec. 31, 2019

Jan. 3, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2019 vs. 2018

Jan. 3, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.
Read More
Hand holding gear, dollar sign

Biopharma money raised by quarter in 2019 (US$M)

Jan. 3, 2020
Biopharma money raised to-date and by quarter in 2019, including public, private and other financings.
Read More

Venture capital and other private biopharma financings in December 2019

Jan. 3, 2020
Venture capital and other private financings of private biopharma companies in December 2019.
Read More

Other financings of public biotechnology companies in December 2019

Jan. 3, 2020
Private placements and other private financings of public biopharma companies in December 2019.
Read More

Follow-on offerings of biopharma companies in December 2019

Jan. 3, 2020
Follow-ons completed by biopharma companies in December 2019.
Read More

Completed and pending biopharma IPOs in December 2019

Jan. 3, 2020
Completed and pending initial public offerings by biopharma companies in December 2019.
Read More

BioWorld and Nasdaq stock indices

Jan. 3, 2020
These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More
Previous 1 2 … 303 304 305 306 307 308 309 310 311 … 323 324 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 27, 2026.
  • Drug capsule spilling onto brain

    Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

    BioWorld Science
    Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • EMA logo on mobile screen, vials, syringes

    Daybu readthrough in EU? Zevra’s NPC bid flounders

    BioWorld
    Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
  • Business pipeline illustration

    Transcripta Bio raises funding to advance neuro pipeline

    BioWorld Science
    Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing